<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142225">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01249430</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02554</org_study_id>
    <secondary_id>NCI-2011-02554</secondary_id>
    <secondary_id>CDR0000689575</secondary_id>
    <secondary_id>OSU-10093</secondary_id>
    <secondary_id>OSU 10093</secondary_id>
    <secondary_id>8803</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT01249430</nct_id>
  </id_info>
  <brief_title>Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1 Study of Azacitidine in Combination With MEC (Mitoxantrone, Etoposide, Cytarabine) in Relapsed and Refractory Acute Myeloid Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I clinical trial is studying the side effects and best dose of azacitidine when
      given together with mitoxantrone, etoposide phosphate, and cytarabine in treating patients
      with relapsed or refractory acute myeloid leukemia. Azacitidine may stop the growth of
      cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
      chemotherapy, such as mitoxantrone, etoposide phosphate, and cytarabine, work in different
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them
      from dividing. Azacitidine may help mitoxantrone, etoposide phosphate, and cytarabine work
      better by making cancer cells more sensitive to the drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximum-tolerated dose of azacitidine when combined with salvage
      chemotherapy comprising mitoxantrone hydrochloride, etoposide phosphate, and cytarabine
      (MEC) in patients with relapsed or refractory acute myeloid leukemia (AML).

      SECONDARY OBJECTIVES:

      I. To define the qualitative and quantitative toxicities of azacitidine in combination with
      MEC with regard to organ specificity, time course, predictability, and reversibility.

      II. To document the rate of complete remission (CR) and CR with incomplete blood count
      recovery (CRi) in patients treated with this combination of agents.

      III. To determine the overall survival, relapse-free survival, and event-free survival of
      patients treated with this combination of agents.

      IV. To evaluate the pharmacokinetics of azacitidine when given in combination with MEC in
      patients enrolled on this study. (Exploratory) V. To measure R2 down regulation, including
      changes in R2 target, AraCTP, and dNTP/NTP pools, of azacitidine when given in combination
      with MEC and to correlate these pharmacodynamic endpoints with clinical response.
      (Exploratory) VI. To evaluate hypomethylation, including DMNT1 expression, Sp1 expression,
      global DNA methylation, gene expression profiling, and microRNA expression profiling, of
      azacitidine when given in combination with MEC and to correlate these pharmacodynamic
      changes with clinical response. (Exploratory)

      OUTLINE: This is a dose-escalation study of azacitidine.

      Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride
      IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6
      hours on days 3-8 in the absence of disease progression or unacceptable toxicity. Treatment
      may repeat every 8 days for 1 additional course. Blood and bone marrow samples are collected
      at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies.

      After completion of study therapy, patients are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose of azacitidine when combined with salvage chemotherapy (mitoxantrone hydrochloride, etoposide, and cytarabine [MEC]) via National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0</measure>
    <time_frame>By day 42</time_frame>
    <description>Frequency distributions and other descriptive measures will form the basis of the analysis of these variables</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response according to the International Working Group criteria</measure>
    <time_frame>Day 42</time_frame>
    <description>Responses will be summarized by simple descriptive summary statistics delineating complete and lesser responses as well as stable and progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative and quantitative toxicities of azacitidine in combination with MEC graded via NCI CTCAE v4.0</measure>
    <time_frame>Up to 30 days post-therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1</condition>
  <condition>Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A</condition>
  <condition>Adult Acute Promyelocytic Leukemia With PML-RARA</condition>
  <condition>Alkylating Agent-Related Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6 hours on days 3-8 in the absence of disease progression or unacceptable toxicity. Treatment may repeat every 8 days for 1 additional course. Blood and bone marrow samples are collected at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)</arm_group_label>
    <other_name>5 AZC</other_name>
    <other_name>5-AC</other_name>
    <other_name>5-Azacytidine</other_name>
    <other_name>5-AZC</other_name>
    <other_name>Azacytidine</other_name>
    <other_name>Azacytidine, 5-</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>Mylosar</other_name>
    <other_name>U-18496</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)</arm_group_label>
    <other_name>CL 232315</other_name>
    <other_name>DHAD</other_name>
    <other_name>DHAQ</other_name>
    <other_name>Dihydroxyanthracenedione Dihydrochloride</other_name>
    <other_name>Mitoxantrone Dihydrochloride</other_name>
    <other_name>Mitoxantroni Hydrochloridum</other_name>
    <other_name>Mitozantrone Hydrochloride</other_name>
    <other_name>Mitroxone</other_name>
    <other_name>Neotalem</other_name>
    <other_name>Novantrone</other_name>
    <other_name>Onkotrone</other_name>
    <other_name>Pralifan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed acute myeloid leukemia

               -  Relapsed or refractory disease according to 2008 WHO classification

          -  Must have failed ≥ 1 course of induction chemotherapy or relapsed after achieving a
             complete remission after induction therapy

          -  No active central nervous system disease or granulocytic sarcoma as sole site of
             disease

          -  ECOG performance status (PS) 0-2 (Karnofsky PS 60-100%)

          -  Life expectancy &gt; 6 months for any comorbid conditions

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN

          -  Creatinine ≤ 1.5 mg/dL

          -  LVEF ≥ 40%

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to azacitidine, mannitol, or other agents used in the study

          -  No uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Serious cardiac arrhythmia

               -  Psychiatric illness and/or social situations that would limit compliance with
                  study requirements

          -  None of the following:

               -  Myocardial infarction within the past 6 months

               -  NYHA class III or IV heart failure

               -  Uncontrolled angina

               -  Severe uncontrolled ventricular arrhythmias

               -  Electrocardiographic evidence of acute ischemia or active conduction system
                  abnormalities

          -  Patients with active infection allowed provided the infection is controlled

          -  No other concurrent anticancer agents or therapies, including chemotherapy,
             radiotherapy (including palliative), or biologic response modifiers

          -  Prior autologous or allogeneic stem cell transplantation allowed

          -  Recovered from non-hematologic toxicity to &lt; grade 2

          -  More than 2 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas
             or mitomycin C)

          -  More than 14 days since prior and no other concurrent investigational agents

          -  No concurrent combination antiretroviral therapy for HIV-positive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Klisovic</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>November 25, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
